Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$73.52
-8.8%
$92.07
$62.70
▼
$148.83
$6.44B1.361.43 million shs14.85 million shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$41.36
-5.2%
$60.06
$37.43
▼
$95.49
$5.85B1.342.27 million shs3.91 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$50.76
-1.4%
$62.35
$50.32
▼
$88.31
$7.07B0.452.11 million shs1.43 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$25.45
-4.9%
$30.44
$25.08
▼
$56.05
$1.84B1.071.61 million shs1.37 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-3.76%-10.55%-12.86%-29.81%-28.57%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+1.25%-7.42%-25.92%-49.89%+12.01%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.27%-8.37%-19.53%-33.03%-20.57%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
+4.57%-7.89%-11.01%-17.13%-6.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$73.52
-8.8%
$92.07
$62.70
▼
$148.83
$6.44B1.361.43 million shs14.85 million shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$41.36
-5.2%
$60.06
$37.43
▼
$95.49
$5.85B1.342.27 million shs3.91 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$50.76
-1.4%
$62.35
$50.32
▼
$88.31
$7.07B0.452.11 million shs1.43 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$25.45
-4.9%
$30.44
$25.08
▼
$56.05
$1.84B1.071.61 million shs1.37 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-3.76%-10.55%-12.86%-29.81%-28.57%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+1.25%-7.42%-25.92%-49.89%+12.01%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.27%-8.37%-19.53%-33.03%-20.57%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
+4.57%-7.89%-11.01%-17.13%-6.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.88
Moderate Buy$155.00110.82% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.73
Moderate Buy$98.71138.65% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.86
Moderate Buy$106.50109.82% Upside
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
2.80
Moderate Buy$74.93194.41% Upside

Current Analyst Ratings Breakdown

Latest VERA, ARWR, ABVX, and CYTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Lower Price TargetOverweight$103.00 ➝ $100.00
11/17/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Lower Price TargetBuy$108.00 ➝ $105.00
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingSell (D-)
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingOutperform$100.00
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Lower Price TargetBuy$104.00 ➝ $96.00
11/6/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Set Price Target$87.00
11/6/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Lower Price TargetBuy$76.00 ➝ $66.00
11/6/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Lower Price TargetNeutral$34.00 ➝ $29.00
11/6/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Lower Price TargetBuy$90.00 ➝ $75.00
11/5/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetBuy$99.00 ➝ $105.00
11/5/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Lower Price TargetOutperform$103.00 ➝ $100.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$450.82M12.97N/AN/A$0.36 per share114.90
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$88.04M80.31N/AN/A($2.31) per share-21.97
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$4.61 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$6.06N/AN/AN/AN/A-91.69%-71.96%12/21/2026 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$724.21M-$5.11N/AN/AN/A-160.64%-172.62%-37.51%2/4/2027 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$6.04N/AN/AN/A-686.63%N/A-48.26%N/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$299.61M-$5.90N/AN/AN/AN/A-90.03%-70.54%N/A

Latest VERA, ARWR, ABVX, and CYTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$1.62-$1.30+$0.32-$1.30$3.42 million$10.28 million
11/4/2026Q3 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.43-$1.37+$0.06-$1.37$41.88 million$47.56 million
9/21/2026Q2 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9170-$1.71-$0.7930-$1.68$0.80 million$1.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
5.97
5.97
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
16.61
4.14
4.11
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
3.36
3.36
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.23
7.91
7.78

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.60%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.60%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
15.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9887.55 millionN/AOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1,062141.37 million136.28 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
673139.30 million135.68 millionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
36272.30 million60.80 millionOptionable

Recent News About These Companies

Vera Therapeutics Earnings Call Highlights TRUTAKNA Momentum
J.P. Morgan Remains a Buy on Vera Therapeutics (VERA)
HC Wainwright Lifts Earnings Estimates for Vera Therapeutics
Vera Therapeutics (VERA) Receives a Hold from Wedbush
Vera Therapeutics Q3 Earnings Call Highlights
Vera Therapeutics (VERA) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abivax stock logo

Abivax NASDAQ:ABVX

$73.52 -7.13 (-8.84%)
Closing price 03:58 PM Eastern
Extended Trading
$74.49 +0.97 (+1.32%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$41.36 -2.29 (-5.24%)
Closing price 03:59 PM Eastern
Extended Trading
$41.37 +0.01 (+0.02%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$50.76 -0.70 (-1.36%)
Closing price 03:59 PM Eastern
Extended Trading
$51.54 +0.79 (+1.55%)
As of 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vera Therapeutics stock logo

Vera Therapeutics NASDAQ:VERA

$25.45 -1.30 (-4.86%)
Closing price 04:00 PM Eastern
Extended Trading
$25.44 -0.01 (-0.04%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.